Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) - a Prospective Multicenter Observational Cohort Study

NCT05326308 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT05326308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05326308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) - a Prospective Multicenter Observational Cohort Study
Lead sponsor
iOMEDICO AG
Phase
Observational
Overall status
Recruiting
Start date
April 26, 2022
Completion date
August 31, 2028
Enrollment
845 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, waldenström's macroglobulinemia